Current Report Filing (8-k)
July 16 2020 - 04:29PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 16, 2020
CYTRX
CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-15327
|
|
58-1642740
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(IRS
Employer
Identification
No.)
|
11726
San Vicente Boulevard, Suite 650
Los
Angeles, California 90049
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code: (310) 826-5648
Former
name or former address, if changed since last report: None
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[X]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
Common Stock,
par value $0.001 per share
|
|
CYTR
|
|
OTC Markets
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth
company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
On July 16, 2020, CytRx
Corporation (the “Company”) announced it has postponed the Company’s 2020 Annual Meeting of Stockholders
(the “Annual Meeting”), previously scheduled for July 30, 2020. The Company has not yet set a new date for
the Annual Meeting and will announce such date at a later time. Once the Company schedules a new date for the Annual Meeting,
it will announce the new deadline for submitting shareholder proposals pursuant to Rule 14a-8 under the Securities Exchange Act
of 1934, as amended.
Important Additional Information
The Company, its directors and certain
of its executive officers are participants in the solicitation of proxies from the Company’s stockholders in connection
with the Company’s 2020 Annual Meeting of Stockholders. The Company intends to file a definitive proxy statement and proxy
card with the Securities and Exchange Commission (the “SEC”) in connection with any such solicitation of proxies
from the Company’s stockholders. STOCKHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ SUCH PROXY STATEMENT, ACCOMPANYING
PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE AS THEY WILL
CONTAIN IMPORTANT INFORMATION. The Company’s definitive proxy statement, dated June 12, 2020, contains information regarding
the direct and indirect interests, by securities holdings or otherwise, of the Company’s directors and executive officers
in the Company’s securities. If the holdings of the Company’s securities change from the amounts provided in the Company’s
definitive proxy statement dated June 12, 2020, such changes will be set forth in SEC filings on Forms 3, 4, and 5, which can
be found through the Company’s website at www.cytrx.com in the “Investors” section under “SEC Filings” or
through the SEC’s website at www.sec.gov. Information can also be found in the Company’s other SEC filings, including
its Annual Report on Form 10-K for the year ended December 31, 2019. Updated information regarding the identity of potential participants,
and their direct or indirect interests, by security holdings or otherwise, will be set forth in a definitive proxy statement and
other materials to be filed with the SEC in connection with the 2020 Annual Meeting of Stockholders. Stockholders will be able
to obtain the definitive proxy statement, any amendments or supplements to the proxy statement and other documents filed by the
Company with the SEC at no charge at the SEC’s website at www.sec.gov. Copies will also be available at no charge at the
Company’s website at www.cytrx.com in the “Investors” section under “SEC Filings”.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
By:
|
/s/
John Y. Caloz
|
Date: July 16, 2020
|
Name:
|
John Y. Caloz
|
|
Title:
|
Chief Financial Officer
|
CytRx (QB) (USOTC:CYTR)
Historical Stock Chart
From Feb 2024 to Mar 2024
CytRx (QB) (USOTC:CYTR)
Historical Stock Chart
From Mar 2023 to Mar 2024